{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasma+infusion", "query": { "intervention": "Plasma infusion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 264, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasma+infusion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T00:26:11.400Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00941720", "title": "Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2009-06-11", "completion_date": "2013-02-28", "has_results": true, "last_update_posted_date": "2020-07-24", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941720" }, { "nct_id": "NCT00731588", "title": "Red Blood Cell (RBC) Survival Following Transfusion in Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neonatal Anemia" ], "interventions": [ { "name": "Transfused Biotin RBCs - Adults Phase I", "type": "BIOLOGICAL" }, { "name": "Transfused Biotin RBCs - Infants Phase II", "type": "BIOLOGICAL" }, { "name": "Transfused Biotin RBCs - Infants Phase III", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "John A Widness", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Hour", "maximum_age": "6 Months", "sex": "ALL", "summary": "1 Hour to 6 Months" }, "enrollment_count": 140, "start_date": "2008-06", "completion_date": "2018-03-02", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 2, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00731588" }, { "nct_id": "NCT02735707", "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia, Influenza, COVID-19" ], "interventions": [ { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Moxifloxacin or Levofloxacin", "type": "DRUG" }, { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" }, { "name": "Amoxicillin-clavulanate", "type": "DRUG" }, { "name": "Standard course macrolide", "type": "DRUG" }, { "name": "Extended course macrolide", "type": "DRUG" }, { "name": "No systemic corticosteroid", "type": "OTHER" }, { "name": "Fixed-duration Hydrocortisone", "type": "DRUG" }, { "name": "Shock-dependent hydrocortisone", "type": "DRUG" }, { "name": "Fixed-duration higher dose Hydrocortisone", "type": "DRUG" }, { "name": "No antiviral agent for influenza", "type": "OTHER" }, { "name": "Five-days oseltamivir", "type": "DRUG" }, { "name": "Ten-days oseltamivir", "type": "DRUG" }, { "name": "No antiviral agent for COVID-19", "type": "OTHER" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Hydroxychloroquine + lopinavir/ritonavir", "type": "DRUG" }, { "name": "Ivermectin", "type": "DRUG" }, { "name": "No immune modulation for COVID-19", "type": "OTHER" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Local standard venous thromboprophylaxis", "type": "DRUG" }, { "name": "Therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "Conventional low dose thromboprophylaxis", "type": "DRUG" }, { "name": "Intermediate dose thromboprophylaxis", "type": "DRUG" }, { "name": "Continuation of therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "No immunoglobulin", "type": "OTHER" }, { "name": "Convalescent plasma", "type": "BIOLOGICAL" }, { "name": "Delayed administration of convalescent plasma", "type": "BIOLOGICAL" }, { "name": "No vitamin C", "type": "OTHER" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "No antiplatelet", "type": "OTHER" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "P2Y12 inhibitor", "type": "DRUG" }, { "name": "No simvastatin", "type": "OTHER" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Eritoran", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Clinician-preferred mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "Protocolised mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "No renin-angiotensin system inhibitor", "type": "OTHER" }, { "name": "Angiotensin converting enzyme inhibitor", "type": "DRUG" }, { "name": "Angiotensin Receptor Blockers", "type": "DRUG" }, { "name": "ARB + DMX-200", "type": "DRUG" }, { "name": "No cysteamine", "type": "OTHER" }, { "name": "Cysteamine", "type": "DRUG" }, { "name": "Fixed-duration dexamethasone", "type": "DRUG" }, { "name": "Baloxavir Marboxil", "type": "DRUG" }, { "name": "Five-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "Ten-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "No endothelial modulator", "type": "OTHER" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "No Immune Modulator for Influenza", "type": "OTHER" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir + remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "UMC Utrecht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2016-04-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735707" }, { "nct_id": "NCT05069922", "title": "Randomized Trial of Fresh Frozen Plasma Versus Albumin in Acute Burn Resuscitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Burns" ], "interventions": [ { "name": "Fresh Frozen Plasma", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 59, "start_date": "2022-02-17", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05069922" }, { "nct_id": "NCT03829566", "title": "Autologous Transplant To End NMO Spectrum Disorder", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neuromyelitis Optica", "Devic's Disease", "NMO Spectrum Disorder" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "rATG", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "IVIg", "type": "BIOLOGICAL" }, { "name": "Autologous Stem Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2019-11", "completion_date": "2025-11-28", "has_results": false, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829566" }, { "nct_id": "NCT00657358", "title": "The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Lidocaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 22, "start_date": "2008-04", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2017-05-17", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00657358" }, { "nct_id": "NCT06597656", "title": "A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "delandistrogene moxeparvovec", "type": "GENETIC" }, { "name": "Plasmapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "PROCEDURE" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "8 Years", "sex": "MALE", "summary": "4 Years to 8 Years · Male only" }, "enrollment_count": 3, "start_date": "2024-09-18", "completion_date": "2025-08-05", "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 3, "location_summary": "Gainesville, Florida • St Louis, Missouri • Columbus, Ohio", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06597656" }, { "nct_id": "NCT03887741", "title": "Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mild Cognitive Impairment" ], "interventions": [ { "name": "Plasmapheresis", "type": "BIOLOGICAL" }, { "name": "Plasma infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 3, "start_date": "2021-09-15", "completion_date": "2024-02-16", "has_results": false, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03887741" }, { "nct_id": "NCT04382651", "title": "Study of Efficacy and Safety of MAS825 in Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Pneumonia, Impaired Respiratory Function" ], "interventions": [ { "name": "MAS825", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard of Care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2020-06-11", "completion_date": "2021-04-21", "has_results": true, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 21, "location_summary": "Chula Vista, California • Glendale, California • Irvine, California + 17 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04382651" }, { "nct_id": "NCT03178695", "title": "Inovium Ovarian Rejuvenation Trials", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Perimenopausal Disorder", "Menopause", "Menopause, Premature", "Menopause Related Conditions", "Menopause Premature Symptomatic", "Menopause Premature Asymptomatic", "Premature Ovarian Failure", "Premature Ovarian Failure, Familial", "Premature Ovarian Failure 2A", "Premature Ovarian Failure 3", "Premature Ovarian Failure 4", "Premature Ovarian Failure 1", "Premature Ovarian Failure 5", "Premature Ovarian Failure 6", "Premature Ovarian Failure 7", "Premature Ovarian Failure 9", "Premature Ovarian Failure 8", "Infertility", "Infertility, Female", "Infertility Unexplained" ], "interventions": [ { "name": "Autologous PRP injection into human ovarian tissue", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ascendance Biomedical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "FEMALE", "summary": "35 Years and older · Female only" }, "enrollment_count": 200, "start_date": "2017-06-01", "completion_date": "2018-05-01", "has_results": false, "last_update_posted_date": "2020-04-20", "last_synced_at": "2026-09-02T00:26:11.400Z", "location_count": 1, "location_summary": "Carlsbad, California", "locations": [ { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03178695" } ] }